Clinical Trials Logo
  1. Home
  2. Melanoma Stage III
  3. NCT04675346

Exploring Unmet Needs and Attitudes to Skin Self-examination in Melanoma Survivors — EUNASS  

Melanoma Stage III Clinical Trial

Official title:
Exploring Unmet Needs and Attitudes to Skin Self-examination in Melanoma Survivors

Clinical Trial Summary

This is a prospective, multi-centred cohort study whereby the EUNASS Study questionnaire will be administered electronically to identify needs of melanoma survivors, the extent to which these needs are being met, and identify areas which have the greatest need for development. It will also evaluate behaviour in relation to sun protection and skin self-examination (SSE). It will be a self-completed questionnaire. Qualitative work using semi-structured interviews will explore the needs of melanoma survivors in greater depth, will present examples of potential interventions to improve SSE and explore factors that determine the likelihood of engaging in an intervention which can address unmet needs, such as improving SSE. Taken together, the data will provide the evidence base to inform the development of an intervention to improve SSE, which can subsequently be tested in secondary care services.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04675346
Study type Observational
Source Oxford University Hospitals NHS Trust
Contact
Status Completed
Phase
Start date November 18, 2020
Completion date September 30, 2022
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04330430 - Neo-adjuvant T-VEC + Nivolumab Combination Therapy for Resectable Early Metastatic (Stage IIIB/C/D-IV M1a) Melanoma With Injectable Disease Phase 2
Withdrawn NCT04007588 - A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma Phase 2
Recruiting NCT05171374 - pRospective Evaluation of Clinical Outcomes in Patients With metAsTatIс melanOma Treated With dabrafeNib and trAmetinib in reaL practicE
Completed NCT03620019 - Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma Phase 2
Recruiting NCT04562129 - IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients Phase 2
Not yet recruiting NCT05467137 - Sentinel Lymph Node Detection in Patients With Stage Ib-III Melanoma Using MSOT and ICG Phase 4
Recruiting NCT05970497 - A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors Phase 1
Recruiting NCT05370807 - A Clinical Trial of Regorafenib in Patients With Pretreated Advanced Melanoma Phase 2
Recruiting NCT04045691 - Binimetinib Plus Encorafenib Real Life Investigation of Next Generation Melanoma Treatment
Recruiting NCT04513028 - Beta Glucan's Effect on Pembrolizumab Immunologic Response in Stage III-IV Melanoma N/A
Active, not recruiting NCT04207086 - A Phase II Study of Neoadjuvant Pembrolizumab & Lenvatinib for Resectable Stage III Melanoma Phase 2
Completed NCT03153085 - A Study of Combination With TBI-1401(HF10) and Ipilimumab in Japanese Patients With Unresectable or Metastatic Melanoma Phase 2
Recruiting NCT04741997 - Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma Early Phase 1
Active, not recruiting NCT04526899 - Trial With BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Anti-PD-1-refractory/Relapsed, Unresectable Stage III or IV Melanoma Phase 2
Not yet recruiting NCT05827770 - The Efficacy and Safety of Neoadjuvant Toripalimab Combined With Temozolomide in Resectable Stage III Melanoma Phase 2
Recruiting NCT04598009 - Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma Phase 2
Recruiting NCT05751928 - A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin Melanoma Phase 3
Recruiting NCT05402059 - Clinical Outcomes and Biomarkers in Patients With Stage 0-IV Melanoma in Real Clinical Practice
Recruiting NCT05289193 - CD8+ T Cell Imaging During Pre-surgery Immunotherapy in People With Melanoma Phase 2
Not yet recruiting NCT06204991 - To Evaluate the Safety and Efficacy of ADP-TILIL7 in Patients With Locally Advanced or Metastatic Melanoma Phase 1